Q1 2026 Heron Therapeutics Inc Earnings Call Transcript
Key Points
- Heron Therapeutics Inc (HRTX) reported a strong recovery in March with over $15 million in net sales, indicating resilience and underlying business strength.
- The company achieved a 32% revenue growth in its Acute Care portfolio, with ZYNRELEF growing 27% and APONVIE growing over 50% year-over-year.
- The IGNITE program has been successful, leading to a 111% growth in ZYNRELEF unit volume within targeted accounts, prompting an expansion of the program.
- APONVIE has been included in the fifth consensus guidelines for the management of postoperative nausea and vomiting, providing a clinical endorsement that is expected to drive adoption.
- Heron Therapeutics Inc (HRTX) is expanding its sales force in Q3 2026, which is anticipated to be a significant catalyst for growth across its portfolio.
- The first quarter of 2026 was impacted by severe weather, leading to a decline in elective surgeries and affecting overall performance.
- Gross margin for the quarter was 69%, below the typical low to mid-70s percent range, due to higher costs from a secondary supplier for CINVANTI.
- Adjusted EBITDA was negative $727,000 for the quarter, reflecting the impact of storm-related revenue softness and temporary gross margin pressure.
- The company faces increased competitive pressure in the oncology segment, although CINVANTI maintained a 25% market share.
- There is ongoing friction in the adoption of ZYNRELEF, with challenges in reaching a meaningful number of accounts to drive quarter-over-quarter growth.
Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2026 conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Melissa Jarel, Vice President of Legal. You may begin.
Thank you, operator, and hello, everyone. Thank you for joining us on the Heron Therapeutics conference call today to discuss the company's financial results for the first-quarter 2026. With me today from Heron are Craig Collard, Chief Executive Officer; Ira Duarte, Executive Vice President and Chief Financial Officer; Bill Forbes, Executive Vice President and Chief Development Officer; Mark Hensley, Chief Operating Officer; and Kevin Warner, Senior Vice President, Medical Affairs, Strategy and Engagement. For those of you participating via conference call, slides are made available via webcast and can also be accessed via the Investor Relations page of our website following the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
